Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

about

Idelalisib may have the potential to increase radiotherapy side effects.MATLAB®-based fitting method to evaluate survival fractions after multimodal treatment.

P2860

Q32186978-061B8286-7C99-477C-981E-6C632C875135 Q55364931-15125014-CDB0-45DF-A4DB-62CE83D86D2D

P2860

Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

Item

http://www.wikidata.org/entity/Q38788138

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Radiosensitization in esophage ...... polo-like kinase 1 inhibition.

@en

type

Item

label

Radiosensitization in esophage ...... polo-like kinase 1 inhibition.

@en

prefLabel

Radiosensitization in esophage ...... polo-like kinase 1 inhibition.

@en

P1476

Radiosensitization in esophage ...... polo-like kinase 1 inhibition

@en

P2093

Fu-Shan Jaw

http://www.w3.org/2001/XMLSchema#string

Jason Chia-Hsien Cheng

http://www.w3.org/2001/XMLSchema#string

Jenny Ling-Yu Chen

http://www.w3.org/2001/XMLSchema#string

Jo-Pai Chen

http://www.w3.org/2001/XMLSchema#string

Ming-Hsien Tsai

http://www.w3.org/2001/XMLSchema#string

Ming-Jium Shieh

http://www.w3.org/2001/XMLSchema#string

Yu-Sen Huang

http://www.w3.org/2001/XMLSchema#string

Yuan-Chun Tsai

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

polo encodes a protein kinase homolog required for mitosis in Drosophila

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Accelerated repopulation as a cause of radiation treatment failure in non-small cell lung cancer: review of current data and future clinical strategies.

Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.

Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA.

P2888

s00066-016-0951-6

P304

260-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00066-016-0951-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P50

Sung-Hsin Kuo

P577

2016-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015249354

http://www.w3.org/2001/XMLSchema#string

P698

26952039

http://www.w3.org/2001/XMLSchema#string

Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

about

P2860

P2860

Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698